As FDA Review Looms, Drug Cos. Defend Vytorin Study

Law360, New York (January 24, 2008, 12:00 AM EST) -- Merck & Co. and Schering-Plough Corp. continued to defend a controversial study of their Vytorin and Zetia cholesterol treatments Friday on the heels of the U.S. Food and Drug Administration announcing that it will review the study once it receives the final results.

The FDA said that it will take about six months to fully evaluate the data once it receives the final so-called Enhance study.

“After reviewing the data from the Enhance study, and considering all other available information about the link between LDL (bad...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.